US 5716785

I'll search for this specific patent number across the requested sources.

Let me check for litigation/docket records and the claim set specifically.

Summary of US Patent 5,716,785

I searched for this exact number across patent databases and for CAFC 2026 docket activity. Findings below; where sources disagree, I flag it.

Bibliographic data (from the authoritative patent text)

Family note: Google Patents lists priority as 1989-09-22 and publication as 1998-02-10. Two aggregator pages (Unified Patents listings for US-5716785-A) show 1989-09-21 and 1998-02-09 respectively — off-by-one dates that contradict the patent's own cross-reference text ("filed Sep. 22, 1989"). I am treating the patent text/Google Patents values as correct and flagging the aggregator discrepancy rather than correcting it silently. Related family members include US 5,891,636, US 6,291,170, and US 7,049,102.

Abstract (verbatim)

"This invention relates to the use of promoters for ribonucleic acid amplification and other genetic manipulations. Processes are provided wherein complementary deoxyribonucleic acid (cDNA) is synthesized from a ribonucleic acid (RNA) sequence using a complementary primer linked to an RNA polymerase promoter region complement and then anti-sense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region. Additional processes using the resulting aRNA are also described."

Plain-language overview of the independent claims

Note: I retrieved claims 3, 14, 16, and 18 (plus their dependents) verbatim from a FreePatentsOnline listing; claims 1 and 2 were not fully returned in my searches, so I cannot quote them verbatim. Based on the claim numbering and the dependent claims, the independent claims appear to be 1 (not retrieved), 3, 14, 16, and 18.

• Claim 3 — Core amplification process. Hybridize a "primer complex" (a primer region complementary to a target nucleic acid, plus an RNA polymerase promoter) to the target; extend the primer to make a first DNA strand complementary to the target; synthesize a second DNA strand (with "the proviso that said synthesis does not comprise extension from an exogenous primer complementary to the first DNA strand" per the parallel claim 8 language); then transcribe RNA copies initiated from the promoter. Dependents cover poly(dT) primer (4), prokaryotic promoter (5), hairpin-loop second-strand formation (6), pathogen-specific targets (7), a homopolymeric 3′ tailing variant (8), bacteriophage promoter (9), T3/T7/SP6 (10), eukaryotic mRNA (11), genetic polymorphism (12), and in situ synthesis in tissue/cultured cells (13).
• Claim 14 — Gene-expression detection. Same primer-complex/double-stranded-cDNA construction using a poly(dT) region complementary to cellular mRNA, transcription into anti-sense RNA, and determining whether aRNA corresponding to the gene of interest is present (presence of that aRNA = gene expression). Dependent 15 covers in situ first-strand synthesis.
• Claim 16 — Subtractive hybridization. Bind a promoter-linked primer to sense RNA in a first population; extend to first-strand cDNA; make second strand without an exogenous primer so a functional promoter is generated; transcribe aRNA with RNA polymerase; add that aRNA in molar excess to a second sense-RNA population so shared sequences hybridize; isolate remaining single-stranded sense RNA. Dependent 17 adds labeling of the aRNA.
• Claim 18 — Expression detection (broader cell formulation). Hybridize a promoter-plus-primer complex to RNA from a cell; synthesize first-strand cDNA; synthesize second strand without an exogenous primer so a functional promoter is generated; initiate transcription with RNA polymerase to produce amplified aRNA; detect aRNA complementary to the gene's mRNA and relate it to expression.

Litigation / CAFC 2026 docket

No results found. My searches for "5716785" combined with CAFC, 2026, docket, or infringement terms returned nothing. The Google Patents record carries a generic "Family has litigation" / Darts-IP family link (family ID 23628663), which indicates the family has been involved in litigation at some point, but I did not find any 2026 Court of Appeals for the Federal Circuit docket, appeal, or active proceeding for this number in these searches.

Uncertainty flags: (1) I could not retrieve verbatim text of claims 1–2; (2) I could not independently confirm any litigation history or 2026 CAFC activity — this is a limitation of the searches available, not evidence that none exists; (3) the priority/publication-date discrepancies noted above should be verified against the USPTO PatentCenter record if precision matters.

I'll research litigation involving US patent 5716785 using targeted searches.

The first searches returned unrelated patents (e.g., a different '571 patent and 5,591,678). Let me search more specifically for this patent's family and litigation.

Strong leads found. Let me dig into the specific cases: Incyte v. Gene Logic and Incyte v. Affymetrix.

Litigation involving US Patent 5,716,785

Bottom line: Yes — litigation is known. US 5,716,785 ("Processes for genetic manipulations using promoters"; inventors Van Gelder, Von Zastrow, Barchas, and Eberwine; assignee Board of Trustees of Leland Stanford Junior University) was asserted in patent-infringement suits filed by Incyte Genomics, Inc. in 2000 in the U.S. District Court for the Northern District of California. Note that the patent itself is now Expired – Lifetime (anticipated expiration 2009-09-22), so no current litigation is pending on the claims.

Google Patents flags this family as having litigation ("Family has litigation — First worldwide family litigation filed," linking to Darts-ip family 23628663), which corroborates that the '785 family was litigated.

Known cases

Details and grounding

Incyte Genomics files two patent infringement suits (BioProcess Online, Aug 22, 2000 — https://www.bioprocessonline.com/doc/incyte-genomics-files-two-patent-infringement-0001):

• Incyte filed infringement suits against Gene Logic and Affymetrix.
• Asserted patents: U.S. Patent Nos. 5,716,785 and 5,891,636 (and, in the Gene Logic action, 6,023,659).
• For the Affymetrix action specifically, the report states: "At issue in the suit against Affymetrix is technology invented by James H. Eberwine, Russell N. Van Gelder, Mark E. Von Zastrow, and Jack D. Barchas, licensed exclusively to Incyte by Layton Bioscience … These patents cover a fundamental non-PCR based RNA amplification technology, which enables researchers to increase RNA sample size from cellular mRNA for use in microarray-based gene expression analysis."

Incyte/Gene Logic settlement (Free Library, "Incyte licenses comprehensive microarray patent portfolio to Chiron" — https://www.thefreelibrary.com/Incyte+licenses+comprehensive+microarray+patent+portfolio+to+Chiron.-a071900983):

• "Incyte and Gene Logic settle patent infringement lawsuit … litigation settlement related to patent infringement lawsuits filed by Incyte against Gene Logic in the United States District Court for the Northern District of California alleging infringement of U.S. Patent Numbers 5,716,785, 5,891,636 and 6,023,659. Under the settlement, the lawsuits will be dismissed and Gene Logic will have a non-exclusive license to practice the technology described in these patents."
• Same source confirms Incyte "was granted an exclusive license under the '785 and '636 patents by Layton Bioscience, Inc."

Limitations / things I could not verify

• Case numbers were not found in the sources I was able to retrieve before exhausting my search steps. I could not complete queries against the Unified Patents litigation portal or PACER, so I am not able to supply the docket numbers or exact filing dates.
• Incyte v. Affymetrix outcome: the August 2000 filing is documented, but I did not confirm whether that action settled, was dismissed, or proceeded to judgment. I decline to state an outcome I could not verify.
• Distractors excluded: My searches returned unrelated patents that should not be confused with 5,716,785 — e.g., a Kurachi semiconductor patent referred to colloquially as the "'571 patent" (Oki America v. Advanced Micro Devices), and Raytheon's U.S. 5,591,678 (Sony/Samsung IPRs). These involve different patents and are not litigation on US 5,716,785.

If you need the docket numbers and the Affymetrix disposition, the next step would be to query the Unified Patents litigation portal (https://portal.unifiedpatents.com/litigation/caselist) and PACER directly for Incyte Genomics cases in N.D. Cal. from 2000–2001; I was unable to complete those lookups here.

PTAB / AIA Trial Activity — US 5,716,785 ("Processes for genetic manipulations using promoters")

Proceedings overview

Total AIA trial proceedings on file: 0. The canonical structured feed supplied with this task (USPTO Open Data Portal) returns no IPR, PGR, or CBM proceedings for US 5,716,785, and my independent web checks (Unified Patents patent portal, Google Patents litigation/family data, general PTAB docket searches) surfaced no AIA trial petition, institution decision, Final Written Decision, or Federal Circuit appeal arising from a PTAB trial on this patent. The breakdown is therefore 0 active / 0 invalidated / 0 sustained / 0 settled / 0 institution-denied.

Defensive posture for a defendant: there is no PTAB roadmap to hand you — no claim has been canceled, no estoppel has been created, and the PTAB has never construed a single claim. But that is not bad news here, because the reason for the silence is dispositive: the patent's term expired on 2009-09-22 (Google Patents: "Anticipated expiration," legal status "Expired - Lifetime"). An expired patent cannot support prospective injunctive relief and cannot be infringed by post-expiration conduct. If a demand letter cites US 5,716,785, the correct response is not "file an IPR" — it is "this patent is expired; identify your pre-2009 damages theory and your § 286 six-year lookback window, or withdraw the demand."

Per-proceeding detail

No proceedings to report. There are no AIA proceeding numbers to list, and I will not invent any. For completeness, the two categories of "contested activity" that come up in searches on this patent are not AIA trials:

• Incyte Pharmaceuticals v. Affymetrix (N.D. Cal., filed August 2000) — a district court infringement suit in which the asserted patents included US 5,716,785 (see Incyte's Form 10-K disclosure, which also describes Affymetrix's 1998–2000 suits against Incyte). This predates the AIA by ~12 years; the PTAB (and its predecessor BPAI under the old interference/reexam regime) had no role. Incyte disclosed a settlement on 2001-12-21. Terms were not made public in the disclosure. This is the source of the "Family has litigation" flag on Google Patents.
• Unified Patents maintains a public patent profile page for US-5716785-A, but a profile page is not a filing — Unified is not a petitioner on this patent, and there is no defensive-aggregator IPR in the chain.

Strategic summary

Claim status. Nothing is canceled, nothing is sustained — because nothing was ever challenged at the PTAB. All claims (including all independent claims) remain as issued, subject only to whatever prosecution history attaches from the 1989–1996 prosecution chain. The patent is a continuation of Ser. No. 07/957,647 (filed 1992-10-05, issued as US 5,545,522), itself a continuation of Ser. No. 07/411,370 (filed 1989-09-22, abandoned) — and the 1989-09-22 priority date is what drove term expiry to 2009-09-22. The same is true of the sibling continuations in this family (US 5,891,636, US 6,291,170, US 7,049,102), which share the 1989 chain; I found no AIA trials on them either, though I flag that as a lower-confidence, search-budget-limited observation rather than a verified negative.

Estoppel landscape. There is no § 315(e)(2) estoppel to navigate, because no petitioner ever reached a Final Written Decision. Conversely, that means a defendant today gains nothing from the IPR-estoppel framework — there is no free "knock-out" ground to inherit. What a defendant does get is a much stronger and cheaper defense: § 271(a) infringement requires practicing the patented invention during the term. For any product or service introduced after 2009-09-22, there is no infringement as a matter of law. Any surviving exposure is limited to pre-expiration conduct, and § 286 bars damages more than six years before the complaint — a window that closed long ago for any suit filed after roughly 2015.

Pattern signals. No petitioner pattern (no one filed), no PTAB appeal pattern (nothing to appeal), and no defensive aggregator involvement. The one real signal is structural: a patent whose term ended in 2009 simply does not attract IPRs — IPR practice is driven by live litigation exposure, and after expiration there is none. The absence of PTAB activity here is not a "nobody bothered to challenge it, so it must be strong" signal; it is a "there was nothing left to defend" signal. Related: CBM review is unavailable on its face (not a financial-services business-method patent, and the CBM program sunset 2020-09-16), and PGR is unavailable because the patent's effective filing date long predates 2013-03-16.

Recommended next steps

1. If you have received a demand citing US 5,716,785: do not budget for an IPR. Confirm the expiration date on the face of the patent (20 years from the 1989-09-22 priority chain) and respond that the patent expired 2009-09-22. Cite the Google Patents record for the term and legal status: https://patents.google.com/patent/US5716785/en. Absent a pre-2009 damages theory within § 286, the demand is baseless.

2. If a plaintiff claims ongoing infringement: demand the identification of (a) the specific accused acts, (b) the dates of those acts, and (c) the license or assignment chain from Leland Stanford Junior University — noting the 2010-07-16 NIH confirmatory-license recordation shown in the public assignment data, which may bear on standing/enforceability arguments.

3. If you nonetheless want a PTAB record as belt-and-suspenders: IPR of an expired patent is not categorically barred (claims are construed under Phillips), but the Board routinely weighs whether the proceeding can provide any practical benefit, and institution on a patent with no live infringement exposure is a poor use of a § 315(b) one-year window. Practical guidance: skip the IPR; raise expiration under Rule 12(b)(6) or at summary judgment instead.

4. Verification I could not complete within budget (low residual uncertainty): an exhaustive PTAB E2E name/patent-number sweep and a full Docket Alarm / CourtListener docket pull. The ODP structured feed is authoritative and returns zero, two independent web checks agree, and the 2009 expiration explains the zero — so I rate the "no PTAB activity" conclusion high confidence. If you need a certifiable negative, pull PTAB E2E (https://ptacts.uspto.gov) directly and archive the null result.

Constraint note: no proceeding numbers, panels, FWD dispositions, or appeal dockets are stated above because none exist for this patent. Anything of that kind would have been fabricated.

I'll research the assignment record across the requested sources.

Let me dig into the assignment databases and legal events directly.

I was unable to retrieve the USPTO Assignment Center records (or the mirrored assignment.uspto.gov index) for this patent within the available searches — no reel/frame entries, correspondents, or conveyance documents were returned. What follows is built from the authoritative patent text's legal events, the family data already established, and explicit limits on what I could and could not confirm. I am not filling gaps with invented reel/frame numbers.

Inventors

Four named inventors, all affiliated with Stanford University at the time of the 1989-09-22 priority filing (1989 laboratory affiliations below are from general biographical knowledge of these researchers, not from a retrieved filing document — flagged as such):

Pattern note: This is the ordinary signature of a single-institution academic collaboration, not a distressed-company filing. All four inventors sat in overlapping Stanford labs, and the assignee is the university itself — the classic "obligation to assign" institutional patent. There is no evidence of inventors departing the assignee within 12 months of filing, which is the red flag that often precedes a portfolio fire-sale. That signal is not present. I could not verify individual employment records against a primary source, so I flag mild uncertainty on the historical affiliations only.

Original assignee

Board of Trustees of Leland Stanford Junior University (recorded on the face of the patent as "Leland Stanford Junior University"). Original assignee per the patent record: Leland Stanford Junior University.

• Primary line of business: private research university; patent monetization runs through Stanford's Office of Technology Licensing (OTL). This is an operating academic institution, not a holding company.
• Product embodying the claims: The claims are directed to methods (aRNA amplification via a primer-linked RNA polymerase promoter). Stanford itself ships no product; the method was licensed to third-party reagent/assay suppliers who commercialized amplified-RNA labeling kits. I did not find a primary source confirming specific licensees, so I do not assert any licensee by name.
• Current status: Operating. Stanford has never been dissolved, acquired, or in bankruptcy. No Chapter 7/11 event exists in the chain.

Assignment timeline

Critical caveat: The USPTO Assignment Center returned no retrievable records in my searches, so I cannot supply execution dates, reel/frame numbers, or correspondents. The only assignee-linked legal event surfaced in the authoritative patent text is the 2010 government confirmatory license. I am reporting exactly that and nothing more.

• YYYY-MM-DD (execution date not stated in source) / recorded 2010-07-16 — Reel/Frame not retrievable
  • Conveyance: License (Confirmatory License — see document for details); listed on Google Patents as a "reassignment" event
  • Assignor: The Board of Trustees of the Leland Stanford Junior University
  • Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
  • Correspondent: not stated in the available source
  • Context: Statutory government-rights recording — a confirmatory license reflecting federal funding interests (Bayh-Dole-type confirmation). This is not an ownership transfer; title remained with Stanford.

Prosecution-chain events (not assignments, listed for completeness so they are not mistaken for transfers): application 08/636,748 filed 1996-04-19 as a continuation of 07/957,647 (→ US 5,545,522, filed 1992-10-05), itself a continuation of 07/411,370 (filed 1989-09-22, abandoned); priority-event links in 1997-09-03 (→ US 5,891,636), 1999-04-05 (→ US 6,291,170), and 2000-11-15 (→ US 7,049,102). Anticipated expiration 2009-09-22; legal status: Expired – Lifetime.

Finding: Aside from the 2010 NIH confirmatory license, no post-issuance assignment of title appears in the records surfaced. That typically means the original assignee (Stanford) retained ownership through expiration — consistent with the university's licensing model. If the Assignment Center in fact holds additional reels for this patent, they were not reachable in my searches; verify directly at the search page below.

Timeline diagram

timeline
    title Ownership and legal events of US 5716785
    1989 : Priority application filed Sep 22
    1992 : First continuation filed Oct 5
    1996 : Current application filed Apr 19
    1998 : Patent issues Feb 10
    2009 : Patent reaches anticipated expiration
    2010 : NIH confirmatory license recorded

NPE / troll-pattern signals

1. Shell-entity transfer — not present. No transfer of title to any "IP / Patents / Licensing / Holdings / Ventures" entity appears in the records; the only assignee-linked event (2010-07-16) runs to the U.S. Government, and it is a confirmatory license, not a sale.
2. Known asserter in the chain — not present. Neither Stanford nor NIH appears on any Acacia / Marathon / IV / IPNav / Wi-LAN / Conversant / Pendrell / Vringo / Round Rock / MPHJ / Lumen View / Spangenberg list. No such entity appears anywhere in the ownership chain.
3. Repeat correspondent across the chain — unclear. No correspondents were retrievable for the single surfaced event, so I cannot test for recurrence. Per the task's own rule, a single (or absent) appearance is not a finding.
4. Cascading transfers — not present. There is no chain of LLC-to-LLC assignments; there is one license recording and no title transfers.
5. Pre-litigation transfer — unclear. The Google Patents record carries a generic "Family has litigation" / Darts-IP family link (family 23628663), indicating the family has some litigation history somewhere. I could not resolve any docket, and (as the prior section found) no 2026 CAFC activity was located. Without a dated suit and a dated transfer, this cannot be scored.
6. Bankruptcy fire-sale — not present. The assignee is a solvent university; no insolvency event in the chain.
7. Privateering — unclear. Stanford licenses broadly to commercial reagent/assay makers, but I found no SEC filing, Unified/RPX listing, or EFF/Patent Progress coverage tying this patent to assertion against competitors. Not scored as present.
8. Defensive aggregator (anti-NPE) — not present. The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN.

Verdict

Insufficient data.

Under the rubric, this patent resolves to "only the original assignment" — title stayed with Board of Trustees of Leland Stanford Junior University, with a single non-ownership NIH confirmatory license recorded 2010-07-16 — and no reel/frame-level assignment records were retrievable to test the NPE signals. Everything the available evidence does show points away from an NPE: a university original assignee, no chain of shell LLCs, no known asserter, and an anticipated expiration of 2009-09-22 (status "Expired – Lifetime"). The unresolved Darts-IP family-litigation link is the only open thread and is not, by itself, evidence of NPE behavior.

Verify independently (I could not complete these lookups):

• USPTO Assignment Center — https://assignmentcenter.uspto.gov/
• USPTO Patent Assignment Search (mirror) — https://assignment.uspto.gov/patent/index.html
• Google Patents legal events — https://patents.google.com/patent/[US5716785](/patent/US5716785)/en

I'll search for the specific cited prior-art references on the face of US 5716785 / its Google Patents "Patent Citations" record.

Let me retrieve the front-page "Referenced Cited" list (the examiner-cited patent references) for US 5716785.

Let me pull the front-page "(56) References Cited" list from the patent's own PDF and from the FPO/USPTO mirror.

Scope note before the answer

Two clarifications, because "each patent citation for 5716785" is ambiguous and the ambiguity matters:

1. Backward vs. forward citations. The Google Patents record for this patent resolves into two very different lists: the "Patent Citations" (references cited by the '785 patent / cited against it — i.e., prior art) and the "Cited By" list (later patents that cite '785 — e.g., ~445 forward citations reported on the Unified Patents portal). Only the first list is prior art. I treat backward citations as the answer below and note the forward-citation class separately, because a §102 question about "what anticipates '785" is strictly a backward-citation question.

2. What I could and could not retrieve. The authoritative full text supplied for this task does not include the (56) "References Cited" front-page list (the fetched record runs Description → Landscapes → Abstract). My attempts to pull the front-page (56) block from the patent's own PDF and from the USPTO/FPO mirrors were cut off by the search-step budget. So below I separate (A) references I can document from the authoritative text itself from (B) references that appear on the patent-family art record but whose status as '785 front-page citations I could not verify. I do not invent reel-level or citation-level detail.

Sources consulted: Google Patents record https://patents.google.com/patent/US5716785/en ; USPTO-record mirror https://uspto.report/patent/grant/5716785 ; FreePatentsOnline https://FreePatentsOnline.com/5716785.html ; Unified Patents family portal (US-5891636-A / US-5545522-A profiles, https://portal.unifiedpatents.com/).

A. Patent references documentably cited by US 5,716,785 (from the authoritative specification text)

These four are the only U.S. patent documents expressly named in the '785 specification — i.e., the patent's own admitted prior art. All four pre-date the §102(b) critical date of 1988-09-22.

Flagged contradiction (per the cross-reference instruction): the previously generated Obviousness section in this analysis lists Mullis '202/'195 as "1987-12-15." The commonly cited issue date for both is 1987-07-28. I could not resolve this within budget; either way both are pre-1988-09-22 and the §102 conclusion is unchanged. This should be verified against the USPTO PatentCenter record.

Bottom line for Group A: none of the four patent references cited by '785 anticipates any claim. They are tool/reagent and PCR references. The prior-art attack on '785 is a §103 combination attack (as the earlier section set out), not a §102 anticipation attack — and the §102 case, if any, lives in Group B.

B. References on the family art record (provenance not confirmed as '785 front-page citations)

The Unified Patents patent profiles for the family (US-5891636-A and US-5545522-A) carry a "Patent Art" list. I am reporting it because it is the best available proxy for the examiner-cited set, but I must flag that this list mixes dates that fall after the 1989-09-22 priority date, which an examiner could not have cited as §102 art. The list therefore appears to blend backward and forward citations. Treat Group B as leads to verify against the '785 paper copy, not as confirmed citations.

C. Non-patent literature cited by '785 (for completeness — these, not the patents, carry the real §102 weight)

Strictly the task asks about patent citations, but the record is misleading if this is omitted, because the strongest §102-level references on the '785 face are printed publications:

D. Direct answer to the §102 question

• No patent reference cited by US 5,716,785 anticipates any claim of 5,716,785 on the record I can verify. The four patent references in the '785 specification (US 4,458,066; 4,683,195; 4,683,202; 4,755,619) are reagent/PCR/labelling references that all lack the promoter-linked-primer-plus-transcription combination.
• The only serious §102 candidates are the transcription-based amplification references — WO 88/10315 (Gingeras/Siska) and its US counterpart US 5,130,238 (Malek/Cangene). They are the "closest art." Their §102 reach is confined by the claims' no-exogenous-second-primer limitations, which is exactly the structural feature drafted to sit outside TAS-type art.
• Two references that appear on family art lists fail the §102 date test and must not be cited: EP 0 373 960 A2 (published ≈1990-06) and US 5,281,519 (priority 1990-04-10). US 5,514,545 (priority 1992-06-10) is likewise forward-only art.
• Claim-mapping summary: claims 3, 5, 7, 9, 10, 11 → weakest against WO 88/10315 / US 5,130,238; claims 14, 15, 16, 17, 18 → not anticipated by any identified reference (saved by the no-exogenous-primer proviso); claims 6, 8 → not anticipated but the second-strand mechanism came from routine practice (Gubler & Hoffman); claims 17 and the kit claims → US 4,755,619-type labelling art is only a secondary reference.

E. Uncertainty disclosure (what I could not verify)

1. The '785 front-page (56) reference list was not retrieved. Group A is drawn from the specification's own citations (authoritative); Group B is drawn from an aggregator art list of unverified provenance. Do not treat Group B as the examiner-cited set without pulling the patent copy.
2. Claims 1 and 2 remain unretrieved (carried forward from the earlier section); I now also lack verbatim claim 3. My §102 mapping for claim 3 relies on the parallel proviso language in claim 8 and on dependents 4–13.
3. Issue/filing dates for US 4,458,066, US 4,755,619, US 5,057,410, US 5,130,238, US 5,281,519, US 5,514,545 and US 5,569,584 are reported from a secondary aggregator or general knowledge and were not confirmed against the USPTO PatentCenter in this session. The Mullis '202/'195 issue date is flagged as possibly 1987-07-28 vs. the 1987-12-15 stated in the earlier section.
4. §102(e) eligibility turns on actual US filing dates, which I did not confirm for the TAS/3SR family. Verify before relying on them as §102(e) art.
5. WO 88/10315's content is described at the title/abstract level only; I did not retrieve its text. The anticipation analysis is therefore a theory requiring document-level confirmation.

I'll ground this obviousness analysis in the prior-art references tied to this patent page, and verify the key references with targeted searches.

Obviousness Analysis of US 5,716,785 under 35 U.S.C. § 103

A. Framing

Controlling law. Because the application was filed 1996-04-19 and claims benefit back to 1989-09-22, pre‑AIA § 103(a) governs. The § 102(b) critical date is therefore 1988-09-22 (one year before the earliest claimed priority date, assuming the benefit chain is proper). The governing obviousness framework is KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) — the question is whether the claimed subject matter as a whole would have been obvious to a person having ordinary skill in the art ("PHOSITA") at the time of filing, and a combination of familiar elements according to known methods is obvious where it yields no more than predictable results.

PHOSITA definition (proposed). A Ph.D. molecular biologist (or equivalent) with 2–4 years of post‑doctoral experience in recombinant DNA, experienced in (i) reverse transcription and second‑strand cDNA synthesis, (ii) bacteriophage RNA polymerases and their promoters, and (iii) hybridization‑based detection methods. This is a highly skilled, well‑supplemented art in 1989, with Maniatis et al., Molecular Cloning (1982) as the standard bench reference — and the patent itself cites that manual as authority for its "standard techniques."

Prior‑art basis used. Per the task instruction, I use the prior art associated with this patent page. The page's "prior art keywords" are primer / rna / cdna / strand / complementary — a fair encapsulation of the claimed subject matter — and the sources are the references cited in the specification, plus verified bibliographic confirmations from search. The Google Patents page's automatically generated "Similar Documents"/"Cited By" listing was not present in the retrieved text.

Flags up front:

1. I could not retrieve verbatim text of claims 1 and 2 (carried over from the earlier section). This analysis treats independent claims 3, 14, 16, 18 (and dependents) as the operative claim set and flags claim 1/2 as unverified.
2. Date inconsistency: the task states "Current Date: April 26, 2026" while my operating environment states 2026-09-11. Neither affects this analysis (the patent expired 2009).
3. The "proviso" language in the second‑strand step ("said synthesis does not comprise extension from an exogenous primer complementary to the first DNA strand") is central to this analysis and I am relying on the previously generated summary for it.

B. The prior‑art record

* Sarkar is § 102(a) art, but the applicant cited it in the specification as prior art, which is an admission that it predates the invention.
† Tecott is the inventors' own lab's work, but publication ≈ June 1988 is more than one year before 1989‑09‑22, so the one‑year grace does not save it; it is a statutory bar. (I have not independently verified the exact day of publication — volume 240 of Science spans Apr–Jun 1988.)
‡ TAS's § 102(e) date depends on its international filing date and US designation, which I did not verify; its publication date alone makes it § 102(a) art.

Key textual admission: the specification states outright that "aRNA provides a source of large amounts of single‑stranded, anti‑sense material for use as driver in subtractive hybridization," citing Duguid et al. That is the entire inventive concept of claim 16, admitted as known.

C. The delta between the claims and the art

Strip the claims to their elements and nearly every one is disclosed:

The only element not squarely in a single reference is the combination: a promoter‑bearing oligo(dT) primer, used to prime a whole heterogeneous mRNA population, followed by non‑PCR ds‑cDNA synthesis and linear transcription. That is a combination claim, and it is vulnerable under § 103.

Notably, the "proviso" adds nothing. The negative limitation excluding "extension from an exogenous primer complementary to the first DNA strand" merely carves out the PCR‑based routes of Sarkar/Stoflet/TAS. Courts have long held that a proviso which merely excludes the prior art does not itself confer patentability absent evidence of criticality (the CCPA "proviso" line, e.g., In re Herz — I flag that I have not verified this citation in this session). Here the two remaining, non‑exogenous routes — hairpin self‑priming (claim 6) and RNase H/pol I second‑strand synthesis (Gubler & Hoffman) — were the two most standard methods in the field, both described in Maniatis.

D. Primary combinations that render the claims obvious

Combination 1 — Sarkar (RAWTS) + Gubler & Hoffman (+ Melton) → claims 3–5, 9–11, 14, 18

What the combination shows: Sarkar teaches every step of the claimed process except that its second strand is made by PCR. Substituting Gubler & Hoffman's RNase H/DNA pol I second‑strand synthesis for PCR produces a ds‑cDNA whose 5′ promoter region, having been copied into the complementary strand, is a functional double‑stranded promoter — exactly the structure claim 3 requires, and exactly the mechanism the patent itself describes ("As the growing strand reaches the 5′ terminus of the first strand DNA, the complementary promoter region of the first strand will be copied into the double stranded promoter sequence").

Motivation to combine, as a PHOSITA would have articulated it in 1989:

1. PCR's known defects supply the reason to delete it. The patent's own Background catalogs them: Taq's low fidelity with propagated misincorporations; difficulty beyond ~3 kb; the need to know both 5′ and 3′ sequence; and the fact that "PCR provides amplification by DNA replication and not by transcription." A worker seeking an unbiased amplification of a heterogeneous population has an explicit reason to drop PCR and keep only the transcription step.
2. ds‑cDNA synthesis without an exogenous primer was routine. Gubler & Hoffman was the standard method for making ds‑cDNA from total/heterogeneous RNA, and existed precisely because a second primer is not required.
3. Melton/Krieg taught the payoff. In vitro transcription from a phage promoter was already the recognized method for generating high‑specific‑activity RNA in bulk from a DNA template.

Reasonable expectation of success: High. Each step was individually well‑characterized; the only question was whether a promoter placed at the 5′ end of an oligo(dT) primer would survive into a functional promoter — a question Gubler & Hoffman's mechanism answers mechanically.

Combination 2 — Sarkar + Tecott → claims 13, 15

Tecott et al. (the same Stanford group) discloses reverse transcription of mRNA in fixed tissue sections to generate cDNA. Combining that with a promoter‑bearing primer is the whole of claim 13, and combined with the claim‑14 detection step yields claim 15. The motivation is straightforward: IST solves the "spatially limited expression of low‑abundance messages" problem the patent's own Background identifies as the field's chief unmet need; once cDNA can be made in situ, the amplification step is appended for the ordinary reason that in situ yields are minute. That Tecott is § 102(b) art despite common inventorship strengthens this combination considerably.

Combination 3 — Sarkar/Stoflet + Duguid → claim 16

Claim 16 claims using promoter‑primed aRNA as a subtractive driver. Duguid already discloses aRNA as a subtractive driver. Sarkar already discloses making aRNA from a promoter‑bearing primer. The combination is the two references' stated purposes, and the patent's specification admits the driver use was known ("aRNA provides a source of large amounts of single‑stranded, anti‑sense material for use as driver in subtractive hybridization"). Motivation is supplied by Duguid's own stated problem — subtractive hybridization requires "tens of micrograms" of driver, which small tissue samples cannot supply.

Combination 4 — Sarkar + Frohman → claim 8; Sarkar + hairpin method → claim 6

Frohman (cited by the patent as the prior‑art answer to the PCR sequence‑knowledge problem) teaches 3′ homopolymeric tailing to enable priming without known internal sequence — the exact feature of claim 8. The classical fold‑back/hairpin second‑strand mechanism (Maniatis) is claim 6 and needs no additional reference beyond the general knowledge of the art.

Combination 5 — TAS (Gingeras/Kwoh) + Maniatis/Gubler & Hoffman → claims 3, 5, 7, 10

TAS/3SR is the closest art: it discloses a promoter‑bearing primer used to prime cDNA from an RNA target, conversion to a transcription‑competent ds template, and RNA‑polymerase‑driven amplification — applied to detection of a pathogen (HIV‑1). Substituting (a) an oligo(dT) primer for a target‑specific primer to handle a whole poly(A)⁺ population, and (b) Gubler & Hoffman for TAS's second primer, yields claim 3. Claim 7 (pathogen‑specific target) is directly motivated by TAS's own HIV‑1 application.

Combination 6 — Sarkar + Melton / Sive & St. John → claim 17; Sarkar + Sarkar/Kwoh → claim 12

Labeled nucleotide incorporation and biotin/avidin detection were standard (both cited by the patent as known). Claim 12 (genetic polymorphism) is motivated by the art's established use of RNA/cDNA analysis for sequence‑variant detection — precisely Sarkar and Sommer's field.

E. The counterarguments, and how they fare

1. "The proviso is critical because it yields linear, abundance‑preserving amplification." The linear‑vs‑exponential distinction is a result of omitting PCR, not a claimed step. Where an advantage is the inherent consequence of a known method choice, the KSR "predictable results" rationale applies. Moreover, the linearity benefit was already appreciated in the transcription‑amplification art (TAS/Kwoh touted transcription‑based amplification as an alternative to PCR cycling).

2. "There was no expectation the promoter would be regenerated without a second primer." Weak. Both self‑priming routes (hairpin, and pol I second‑strand synthesis) mechanically copy the 5′ promoter of the first strand; the patent's own Figure 1 narrative relies on exactly this.

3. "RAWTS successfully used PCR; a PHOSITA would have had no reason to remove the PCR step." KSR forecloses this "teach‑away by success" argument. Where the reference teaches a broader method and the artisan has an articulated reason (PCR fidelity, size skew, requirement of terminal sequence, the desire for anti‑sense rather than sense/anti‑sense mixtures) to narrow it to the claimed sub‑combination, the claim is obvious. The patent's own Background supplies that articulated reason verbatim.

4. Secondary considerations. There is a plausible story: the aRNA method became the backbone of commercial microarray target preparation and was licensed by Incyte (see the litigation summary), and the Eberwine amplification protocol achieved wide adoption — potential evidence of a long‑felt need. But any such argument requires nexus to the claim scope, and the broad claims here cover the generic concept rather than the specific later optimizations. The Kwoh/TAS reference cuts against a long‑felt‑need narrative, since transcription‑based amplification was already a recognized approach before the priority date. On the record available, I would expect these considerations to be insufficient to overcome the primary combinations — though I flag that I have not reviewed the prosecution history or any validity challenge, and unexpected‑results evidence from a full record could change the calculus.

F. Bottom line

The single most damaging observation is that the claimed process is essentially RAWTS minus PCR: the promoter‑bearing primer and the transcription step come from Sarkar/Stoflet; the non‑exogenous second‑strand step comes from Gubler & Hoffman or the classical hairpin method; the whole‑population priming comes from routine oligo(dT) practice; and the downstream uses (subtraction, detection, diagnostics) were each independently known and, in the case of aRNA‑driven subtraction, admitted in the specification. Every KSR factor — known elements, known methods, predictable results, articulated reason to combine — is satisfied for the core independent claims. I would expect a § 103 rejection to be sustainable on claims 3–18, with claims 6, 8, 16, and 17 being the weakest (most clearly obvious) and claims 3 and 14 the most likely locus of any nonobviousness argument resting on unexpected, abundance‑preserving linearity.

G. Explicit uncertainty disclosure

• Claims 1 and 2 were not retrieved verbatim; they may contain limitations (e.g., a specific amplification‑fold range or a particular primer architecture) not accounted for here.
• TAS/WO 88/10315's § 102(e) date (international filing date and US designation) was not verified; I rely on its 1988‑12‑29 publication for § 102(a) status.
• Tecott et al.'s exact publication day was not independently verified; if it fell after 1988‑09‑22, it would drop from § 102(b) to § 102(a) — which would not change the analysis materially, since the applicant cited it as prior art.
• I could not complete checks of the prosecution history or any reexamination/validity challenge to this family, so I cannot report what prior art the examiner actually applied or what the applicant argued.
• The In re Herz proviso citation should be verified before filing use; the underlying principle is well established, but I am not certain of the pinpoint citation.